KyungDong Pharm home
Prescription Medicines

Fexot tab.40mg

Product Category
Gout treatment
Active Ingredients
facebooksostart
Appearance
A white to pale yellow, round, film-coated tablet.
Reimbursement Code
648104280
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Febuxostat (in-house specification) ------------ 40mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry II white (85F18422), colloidal silicon oxide, croscarmellose sodium, hydroxypropyl cellulose

2. Effectiveness
Treatment of chronic hyperuricemia in gout patients

3. Dosage and dosage
1. Adult
This drug is administered at 40 mg or 80 mg once a day, regardless of meal.
Because this drug works very quickly, serum uric acid levels should be retested after 2 weeks. The goal of treatment is to maintain serum uric acid concentration by lowering it to less than 6 mg/dL (357 μmol/L).
2. Patients with renal impairment
No dose adjustment is necessary in patients with mild to moderate renal impairment. The safety and efficacy of this drug have not been adequately evaluated in patients with severe renal impairment (creatinine clearance less than 30 mL/min).
3. Patients with liver failure
No special dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Limited information is known for patients with moderate hepatic impairment, and the efficacy and safety of this drug have not been studied in patients with severe hepatic impairment (Child Pugh grade C).

4. Precautions for use
1. Warning
1) Cardiovascular death
In the Cardiovascular Safety Study (CARES), it was reported that the cardiovascular mortality rate was higher when patients with gout with cardiovascular disease were treated with this drug than when treated with allopurinol. When deciding whether to administer this drug, the risks and benefits of this drug should be considered. Patients with major cardiovascular disease (e.g. myocardial infarction, stroke, or unstable angina) should avoid receiving this drug if other appropriate treatment is available.

2. Do not administer to the following patients
1) Patients with hypersensitivity to the main ingredient or excipient of this drug
2) Patients taking mercaptopurine or azathioprine
3) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients:
1) Patients with liver disease or a history of liver disease (it is recommended to perform regular liver function tests upon administration)
2) Patients with changes in thyroid function (In long-term open-label clinical trials, thyroid-stimulating hormone (TSH) concentration increased >5.5 μIU/mL in 5.0% of patients who took this drug long-term.)
3) Patients with ischemic heart disease or congestive heart failure
4) Patients taking theophylline (when 80 mg of this drug and 400 mg of theophylline were co-administered to healthy adults, no pharmacokinetic interaction with this drug was observed. Febuxostat 80 mg can be administered in combination with patients receiving theophylline without risk of increasing the blood concentration of theophylline. However, when administered in combination, 1-methylxanthine (theophylline) is excreted in the urine. The amount of metabolite increased by approximately 400 times. There is no known safety information on long-term human exposure to 1-methylxanthine, so caution should be exercised when using it together.
5) Organ transplant recipients (see 5. General precautions)
6) Patients with a history of major cardiovascular disease (e.g. myocardial infarction, stroke, or unstable angina) or cerebrovascular disease
7) Patients with a high rate of uric acid production (e.g., malignant disease and patients undergoing treatment for it, Lesch-Nyhan syndrome) (Rarely, the absolute concentration of urinary xanthine increases and it is deposited in the urinary tract.)

4. Adverse reactions
1) Randomized comparative clinical trial
Phase 2 and 3 clinical trials7) In patients with a high rate of uric acid production, 2,757 patients received 40 mg or 80 mg of this drug per day. 559 people received 40 mg per day for more than 6 months. 1,377 people received 80 mg per day for more than 6 months, 674 people for more than 1 year, and 515 people for more than 2 years. In the CARES clinical trial, a total of 3,098 patients received 40 mg or 80 mg of this drug, of which 2,155 patients received this drug for more than 1 year and 1,539 patients received this drug for more than 2 years. In the FAST clinical trial, a total of 3,001 patients received 80 mg or 120 mg of this drug, with most (97.5%) taking the 80 mg dose. The median duration of exposure to randomized study treatment (time from randomization to discontinuation of the drug) was 1,227 days in the treatment group.
Most Common Adverse Reactions: The most common drug-related adverse reactions observed by investigators reported in three 6-month or 12-month randomized controlled clinical trials (three core trials) are listed in Table 1. Patients who discontinued the clinical trial due to abnormal liver function were 1.8% in the 40mg dose group, 1.2% in the 80mg dose group, and 0.9% in the allopurinol group. In addition, although it was not reported to be more than 0.5% higher than placebo, dizziness was reported in more than 1% of patients treated with this drug. In the CARES clinical trial, liver function abnormalities and diarrhea were not more than 0.5% higher in the drug-treated group than in the allopurinol group, but were more than 1%. Common drug-related adverse events in the FAST clinical trial included diarrhea, headache, rash, nausea, fatigue, liver function test abnormalities, joint pain, dizziness, limb pain, gout, muscle pain, pruritus, and dyspnea, which were reported in more than 1% of the drug-treated group. These drug-related adverse events were predictable side effects of the drug.

[Table 1] Drug-related adverse reactions reported more than 1% and 0.5% higher than placebo in comparative clinical trials
※ Refer to the manual

Adverse reactions reported in phase 2 and 3 clinical trials conducted in the dosage range of 40 to 240 mg. Drug-related adverse reactions reported in less than 1% of cases are listed below by body organ.
- Blood and lymphatic system abnormalities: anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia
- Cardiac abnormalities: angina, atrial fibrillation/atrial flutter, heart murmur, electrocardiogram abnormality, palpitations, sinus bradycardia, tachycardia
- Ear, labyrinth, and eye abnormalities: hearing loss, tinnitus, dizziness, blurred vision
- Gastrointestinal abnormalities: abdominal distension, abdominal pain, constipation, dry mouth, indigestion, flatulence, increased frequency of bowel movements, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gum pain, hematemesis, hyperchlorhydria, bloody stool, oral ulcer, pancreatitis, gastric ulcer, vomiting
- Systemic and administration site abnormalities: asthenia, chest pain/discomfort, edema, fatigue, emotional abnormalities, gait disturbance, influenza-like symptoms, mass, pain, thirst
- Abnormalities in the liver-biliary system: cholelithiasis/dangitis, hepatic steatosis, hepatitis, hepatomegaly
- Immune system abnormalities: hypersensitivity
- Infection: Shingles
- Metabolic and nutritional abnormalities: loss of appetite, decreased appetite/increased appetite, dehydration, diabetes, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight loss/weight gain
- Musculoskeletal and connective tissue abnormalities: arthritis, joint stiffness, joint swelling, muscle spasms/muscle monotony/muscle stenosis/muscle weakness, musculoskeletal pain/muscle stiffness, muscle pain
- Nervous system abnormalities: Changes in taste, balance abnormalities, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental disorder, migraine, paresthesia, drowsiness, transient ischemic attack, tremor.
- Mental abnormalities: nervousness, anxiety, depression, insomnia, excitability, decreased libido, nervousness, panic attacks, personality changes
- Urinary-reproductive system abnormalities: hematuria, nephrolithiasis, urinary frequency, proteinuria, renal failure, insufficient renal function, urinary urgency, urinary incontinence, mastalgia, erectile dysfunction, gynecomastia
- Respiratory system abnormalities: bronchitis, cough, difficulty breathing, nosebleeds, nasal dryness, sinus hypersecretion, pharyngeal edema, airway congestion, sneezing, throat irritation, upper respiratory tract infection
- Skin and subcutaneous tissue abnormalities: alopecia, angioedema, dermatitis, dermographism, ecchymosis, eczema, hair discoloration, hair growth abnormality, hypersweat, skin peeling, petechiae, photosensitivity, itching, purpura, skin discoloration/pigmentation changes, skin lesions, odor abnormality, urticaria.
- Vascular system abnormalities: flushing, facial flushing, high blood pressure, low blood pressure,
- Abnormalities in laboratory tests: prolonged activated partial thromboplastin time (aPTT), increased creatine, decreased bicarbonate, increased sodium, EEG abnormalities, increased glucose, increased cholesterol, increased triglycerides, increased amylase, increased potassium, increased thyroid-stimulating hormone, decreased platelets, decreased hematocrit, decreased hemoglobin, increased MCV, decreased red blood cells, increased creatinine, increased blood urea, increased blood urea/creatinine ratio, Increased CPK, increased ALP, increased LDH, increased PSA, increased/decreased urine output, decreased lymphocyte count, decreased neutrophil count, increased/decreased white blood cell count, abnormal blood coagulation test, increased low-density lipoprotein, prolonged prothrombin time, urine cast, positive white blood cells and protein in urine.
- Other: Bruises
2) Cardiovascular safety
① In the post-marketing clinical trial (CARES), the cardiovascular risk of this drug and allopurinol was compared in patients with gout with major cardiovascular disease, cerebrovascular disease, or diabetes accompanied by vascular disease. The trial was a randomized, double-blind, allopurinol-controlled, non-inferiority demonstration trial in which 3,098 people received this drug and 3,092 people received allopurinol, and the primary endpoint, the risk of MACE (Major Adverse Cardiovascular Events), was compared.
For the primary MACE endpoint, the group using this drug was not inferior to the allopurinol group, but the cardiovascular mortality rate was higher in the group receiving this drug compared to allopurinol [hazard ratio: 1.34, 95% confidence interval: 1.03, 1.73]. 100 patients, 1.1 per 100 patients over 1 year). Acute cardiovascular death was higher in the allopurinol group (83 of 3,098, 2.7%) compared to the allopurinol group (56 of 3,092, 1.8%) and was the most common cause of adjudicated cardiovascular death.
All-cause mortality was higher in the allopurinol group (243 deaths, 7.8%, 2.6 per 100 patients per year) than in the allopurinol group (199 deaths, 6.4%, 2.2 per 100 patients per year) due to the higher rate of cardiovascular deaths. [Risk ratio: 1.22, 95% confidence interval: 1.01, 1.47]

[Table 2] Incidence rate of MACE (Major Adverse Cardiovascular Events) in the CARES study
※ Refer to the manual

② In a post-marketing clinical trial (FAST), the cardiovascular risk of this drug and allopurinol was compared in patients with chronic hyperuricemia over 60 years of age who had at least one cardiovascular risk factor and were taking allopurinol. The study was a prospective, randomized, open-label, blinded, multicenter, non-inferiority trial. Subjects received allopurinol treatment before randomization, and the dose could be adjusted if necessary based on clinical judgment.
3,063 people were randomly assigned to receive the drug and 3,065 to the allopurinol group, and the risk of the primary endpoint, a composite endpoint (cardiovascular death, hospitalization due to non-fatal myocardial infarction or biomarker-positive acute coronary syndrome, and non-fatal stroke) was compared.
For the primary endpoint, the group using this drug (172 composite endpoints, 1.723 per 100 patients over 1 year) was not inferior to the allopurinol group (241 composite endpoints, 2.054 per 100 patients over 1 year) [risk ratio: 0.85, 95% confidence interval 0.70-1.03]. Additionally, the primary endpoints were myocardial infarction and stroke. A subgroup analysis was conducted on patients with a history of acute coronary syndrome, and results were similar between the two groups. (This drug group (65 patients (9.5%)), allopurinol group (83 patients (11.8%)), [hazard ratio: 1.02, 95% confidence interval: 0.74-1.42]. Among the secondary endpoints, the cardiovascular mortality rate was higher in the this drug group (62 cardiovascular deaths, 0.610 per 100 patients for 1 year). It was not inferior to the allopurinol group (82 cardiovascular deaths, 0.677 per 100 patients over 1 year) [hazard ratio: 0.91, 95% confidence interval: 0.66, 1.27].

[Table 3] Primary endpoint (composite endpoint) and cardiovascular mortality of the FAST study
※ Refer to the manual

③ Cardiovascular adverse events and death, one of the endpoints predefined by the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), were determined in randomized comparative clinical trials and long-term extension trials. The incidence of APTC events determined per 100 patients over 1 year in the randomized comparative phase 3 clinical trial is as follows. The placebo group was 0 (95% confidence interval 0.00-6.16), the group administered 40 mg of this drug 0 (95% confidence interval 0.00-1.08), the group administered 80 mg of this drug 1.09 (95% confidence interval 0.44-2.24), and the group administered allopurinol 0.60 (95% confidence interval 0.16-1.53).
In the long-term extension study, the determined APTC event incidence rate was 0.97 (95% confidence interval 0.57-1.56) in the 80 mg treatment group and 0.58 (95% confidence interval 0.02-3.24) in the allopurinol group.
The overall incidence of APTC was higher in the drug-treated group than in the allopurinol-treated group. A relationship with this drug has not been established. Signs and symptoms of myocardial infarction and stroke should be carefully monitored.
3) Clinical trials conducted domestically
In a randomized placebo-controlled clinical trial, when 71 patients were administered 40 mg or 80 mg of this drug for 4 weeks, most drug-related adverse reactions were mild or moderate. The most common adverse reactions that appeared to be causally related to the drug when administering this drug were abnormalities in liver function tests, including increased ALT (14.1%) and increased AST (9.9%). Except for this, all occurred in one subject.
4) Foreign post-marketing survey results
Serious allergic or hypersensitivity reactions, including life-threatening Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and acute anaphylactic reactions or shock, have been rarely reported with the use of this drug. In most cases, these reactions occurred within one month after administration of this drug. Hypersensitivity reactions and/or renal impairment have previously been reported with allopurinol in some, but not all, of these patients. Serious hypersensitivity reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), were associated with fever or hematologic disorders in some cases, and serious hypersensitivity reactions were associated with fever, hematologic disorders, or kidney or liver disorders in some cases.
Although the relationship with this drug is not clear, liver failure, jaundice, liver failure, and liver function abnormalities have been reported in some patients who took this drug.
In a randomized controlled clinical trial, the number of patients whose AST and ALT levels increased to more than three times the upper limit of normal after taking this drug was 2% and 3%, respectively, and in the control group (allopurinol group), it was observed in 2% and 2%, respectively. These abnormalities in liver function tests were observed regardless of the dose of this drug.
Additionally, angioedema, agranulocytosis, and rhabdomyolysis were rarely reported.
5) Domestic post-marketing survey results
① A 6-year post-marketing surveillance study in Korea included 3,510 patients. Adverse events, regardless of causality, were reported in 2.22% (78/3,510 patients; 103 events). Serious adverse events occurred in 0.28% (10/3,510 patients; 15 events): chest pain in 0.06% (2/3,510 patients; 2 events), and hepatic coma, cough, hearing impairment, asthenia, fever, abdominal pain, diarrhea, malignant lung neoplasm, influenza-like symptoms, gastritis, gout, oliguria, and pleural effusion, each in 0.03% (1/3,510 patients; 1 event). Hearing impairment was reported as a serious adverse event for which a causal relationship could not be excluded in 0.03% (1/3,510 patients; 1 event). Unexpected adverse events, regardless of causality, occurred in 0.57% (20/3,510 patients; 20 events): diarrhea in 0.14% (5/3,510 patients; 5 events), toxic hepatitis in 0.06% (2/3,510 patients; 2 events), and pruritic rash, hepatic coma, herpes simplex, fecal incontinence, dysuria, frequent bowel movements, tonsillitis, pleural effusion, allergic rhinitis, foot fracture, oliguria, malignant lung neoplasm, and peripheral arterial occlusive disease, each in 0.03% (1/3,510 patients; 1 event). Unexpected adverse drug reactions for which a causal relationship could not be excluded occurred in 0.06% (2/3,510 patients; 2 events), all reported as toxic hepatitis: 0.06% (2/3,510 patients; 2 events).
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for this drug with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, no new adverse events were identified that were statistically significantly more reported for this drug compared to the adverse cases reported for all other drugs.

5. General precautions
1) Acute gout attack: Do not start taking this drug until the acute gout attack subsides. As with other uric acid-lowering drugs, a temporary increase in gout attacks may be observed due to the movement of uric acid at the beginning of administration, so it is recommended to administer non-steroidal anti-inflammatory drugs or colchicine for at least 6 months to prevent worsening of gout. Even if a gout attack occurs while taking this medicine, do not stop taking it. Gout attacks must be appropriately managed simultaneously with treatment for each patient. Continuous administration of this drug reduces the frequency and intensity of gout attacks.
2) Cardiovascular system
① Cardiovascular death: In the Cardiovascular Safety Evaluation Clinical Trial (CARES trial) conducted on patients with gout accompanied by cardiovascular disease, the cardiovascular mortality rate in the drug-treated group (1.5 per 100 patients for 1 year) was higher than that in the allopurinol group (1.1 per 100 patients for 1 year).
In the FAST clinical trial conducted on patients with chronic hyperuricemia over the age of 60 who had at least one cardiovascular risk factor and were taking allopurinol, the cardiovascular mortality rate in the drug-treated group (62 cardiovascular deaths, 0.610 per 100 patients over 1 year) was higher than that in the allopurinol group (82 cardiovascular deaths, 0.677 per 100 patients over 1 year). It was not inferior. [Risk ratio: 0.91, 95% confidence interval: 0.66, 1.27].
The results of the two studies on the incidence of cardiovascular death were conflicting. Therefore, when deciding whether to administer this drug to this patient group, the risks and benefits of this drug should be considered. Patients should be alerted to signs and symptoms of cardiovascular events and should be provided with information on symptoms of serious cardiovascular events and what measures to take when a cardiovascular event occurs.
② Cardiovascular adverse reactions: In a randomized comparative clinical trial, the incidence of cardiovascular thromboembolism (cardiovascular death, myocardial infarction, stroke) was 0.74 per 100 patients for 1 year, 95% confidence interval 0.36-1.37 in the allopurinol group (0.60 per 100 patients for 1 year, 95% confidence interval). 0.16-1.53). Signs and symptoms of myocardial infarction and stroke should be carefully monitored.
3) Liver function abnormalities: Liver function abnormalities were observed in patients administered this drug in clinical trials and foreign post-marketing surveillance. Therefore, liver function tests (ALT, AST, ALT, total bilirubin) are recommended before and after administration of this drug. If a patient taking this drug shows symptoms related to decreased liver function such as lethargy, loss of appetite, discomfort in the right upper abdomen, melanuria, or jaundice, the drug should be stopped immediately and a liver function test should be performed. If an abnormality is found as a result of a liver function test (ALT rise more than 3 times the upper limit of normal, total bilirubin rise more than 2 times, etc.), the cause of the liver function decline must be determined, and this drug should not be administered again unless the cause is clearly identified. For patients who do not have a significant increase in ALT or total bilirubin and have other causative factors other than this drug, taking this drug can be continued, but caution must be exercised.
4) If the rate of uric acid production increases rapidly, there is a risk of accumulation in the urinary tract, but this can be minimized through appropriate hydration and alkalization of urine.
5) The use of this drug in patients with hyperuricemia without symptoms is not recommended.
6) The use of this drug is not recommended because there is insufficient clinical experience in organ transplant recipients.
7) Administration of this drug may cause drowsiness, dizziness, and numbness, so be careful not to drive, operate machinery, or engage in dangerous activities.
8) In foreign post-marketing surveillance results, rare cases of serious allergic hypersensitivity reactions, including Stevens-Johnson syndrome and anaphylactic reactions, have been reported. Therefore, if such symptoms appear, carefully monitor the patient and immediately discontinue administration. If an allergic reaction or hypersensitivity reaction, including Stevens-Johnson syndrome, acute anaphylactic reaction, or shock, occurs in a patient taking this drug, treatment with this drug should not be restarted.

6. Interaction
1) Mercaptopurine or azathioprine: Although no studies have been conducted on the interaction with this drug, xanthine oxidase inhibitors may increase the levels of mercaptopurine or azathioprine. Considering the mechanism of action, co-administration with this drug, which has an inhibitory effect on xanthine oxidase, should be avoided.
2) Theophylline: As reported in other xanthine oxidase inhibitors, a drug interaction study of Febuxostat was conducted in healthy adults to determine whether inhibiting xanthine oxidase increases the blood concentration of theophylline. As a result, Febuxostat 80mg, administered once daily, had no effect on the pharmacokinetic parameters or safety of theophylline compared to single administration of 400mg theophylline. didn't However, when administered in combination, the amount of 1-methylxanthine (a metabolite of theophylline) excreted in urine increased about 400-fold. There is no known safety information regarding long-term human exposure to 1-methylxanthine, so caution should be exercised when using it together.
3) The drug interaction between cytotoxic chemotherapy and this drug has not been studied. The safety of this drug during cytotoxic chemotherapy has not been established.
4) Naproxen and other glucuronylation inhibitors: This drug is metabolized by UGT (Uridine diphosphate glucuronosyltransferase) enzyme. Drugs that inhibit glucuronylation, such as non-steroidal anti-inflammatory drugs and probenecid, may theoretically affect the excretion of this drug. When naproxen, 250 mg once a day, was co-administered to healthy adults, the Cmax of this drug increased by 28%, AUC by 41%, and t1/2 by 26%. In clinical trials, there was no increase in clinically significant adverse reactions with the administration of naproxen and other non-steroidal anti-inflammatory drugs/Cox-2 inhibitors. If necessary, this drug or naproxen can be administered together without dose adjustment.
5) Glucuronylation inducers: In theory, strong inducers of UGT enzymes may increase the metabolism of this drug and reduce its effectiveness. After starting the administration of glucuronylation inducers, it is recommended to monitor blood uric acid levels 1 to 2 weeks later. Conversely, discontinuation of the inducer may increase the blood concentration of this drug.
6) Colchicine/Indomethacin/Hydrochlorothiazide/Warfarin: This drug does not require dosage adjustment when administered in combination with colchicine, indomethacin, hydrochlorothiazide, and warfarin. Monitoring of anticoagulant function should be considered when starting treatment with this drug in patients taking warfarin or similar drugs.
7) Desipramine/CYP2D6 substrate: No dose adjustment is expected to be necessary when coadministering this drug with other CYP2D6 substrates (e.g., desipramine). This drug showed weak CYP2D6 inhibition in in vivo and in vitro tests. In a study on healthy adults, when 120 mg of this drug was administered once daily, the Cmax and AUC of desipramine increased by 16% and AUC by 22%.
8) Antacids: Co-administration with antacids containing magnesium hydroxide and aluminum hydroxide delayed the absorption of this drug by approximately 1 hour and decreased Cmax by 32%, but there was no significant change in AUC. Therefore, this drug can be administered regardless of the use of antacids.
9) Rosiglitazone/CYP2C8 substrate: Febuxostat showed a weak inhibitory effect on CYP2C8 in in vitro tests, but in a study on healthy adults, when 4 mg of rosiglitazone and 120 mg of this drug were co-administered once daily, there was no effect on the pharmacokinetics of rosiglitazone and its metabolite, N-desmethyl rosiglitazone. This indicates that febuxostat does not inhibit CYP2C8 enzymes in the human body, so no dose adjustment is necessary when co-administering rosiglitazone or other CYP2C8 substrates with febuxostat.

7. Administration to pregnant and lactating women
1) Results from a very limited number of pregnant women did not show any harmful effects of this drug on the health of the pregnant woman or the fetus and newborn. According to non-clinical test data, there were no direct or indirect harmful effects on pregnancy, fetal development and childbirth. The potential risk to humans is unknown. This medicine should not be taken during pregnancy.
2) It is not known whether this drug is secreted in human breast milk. In non-clinical studies, this drug was excreted in breast milk and caused developmental problems in suckling animals. This medicine should not be taken while breastfeeding because the risk to the breast-feeding infant cannot be ruled out.

8. Administration to children and elderly people
1) This drug is not administered to children and adolescents under the age of 18 as there is no clinical experience.
2) No special dosage adjustment is required for elderly people. Of the total patients who participated in clinical trials of this drug, 16% were over 65 years of age, and 4% were over 75 years of age. Although there were no clinically significant differences in safety and efficacy when compared to other age groups, high sensitivity in some elderly patients cannot be ruled out.

9. Treatment in case of overdose
No cases of overdose have been reported. Symptomatic and supportive care should be provided to patients who have taken an overdose.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) There are no special storage conditions for storing this medicine.

11. Pharmaceutical equivalence test information
A. The test drug Febuxostat 80 mg tablets (Genuone Science Co., Ltd.) and the reference drug Fabric tablets 80 mg (SK Chemicals Co., Ltd.) were orally administered once each to 30 healthy adults in a 2×2 cross-over test to measure Febuxostat in the blood. When the comparative evaluation item values (AUCt, Cmax) were log-transformed and statistically processed, the difference in average values was found to be The 90% confidence interval was within log 0.8 to log 1.25, proving biological equivalence.

※ Table: Refer to manual

B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug Febuxostat Tablets 40 mg (Genuone Science Co., Ltd.) submitted comparative dissolution test data with the reference drug Febuxostat Tablets 80 mg (Genuone Science Co., Ltd.), and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.

Note 1. This drug was manufactured using the same raw materials as Genuine Science Co., Ltd.'s Febuxostat Tablets 40 mg and Febuxostat Tablets 80 mg, and the entire process was manufactured by Genuine Science Co., Ltd. using the same manufacturing method.

12. Others
1) In a fertility and early embryo development test in male and female rats, febuxostat was orally administered up to 48 mg/kg/day (40 times the human exposure of 80 mg/day), and there was no effect on fertility and mating rate, and the non-toxic dose (NOAEL) for the next generation animal (F1) was 48 mg/kg/day. Oral administration of up to 48 mg/kg/day in pregnant rats and up to 48 mg/kg/day in pregnant rabbits (51 times the human exposure of 80 mg/day) did not result in maternal or maternal reproductive dysfunction, malformation, or fetal toxicity. As a result of prenatal and postnatal development and maternal function tests performed in rats, survival rate and development during the weaning period were decreased in offspring at 48 mg/kg/day.
2) The chromosomal abnormality test using CHL was positive. The following in vitro and in vivo tests showed no genotoxicity; Reverse mutation test using bacteria, genetic mutation test on mouse lymphoma cells, chromosomal abnormality test on human peripheral blood lymphocytes, micronucleus test on mice and rats, etc.
3) A carcinogenicity test was conducted in which febuxostat was orally administered to male and female rats and mice for 2 years. Transient cell carcinoma and papillomas of the urinary bladder were observed at 24 mg/kg/day in male rats (25 times the exposure of the human dose of 80 mg) and 18.75 mg/kg in female mice (12.5 times the exposure of the human dose of 80 mg), and were significant in male rats. Tumors of the urinary bladder are thought to be secondary consequences of renal stone formation in the kidneys and urinary bladder.
4) Clinical trial information
To evaluate cardiovascular safety, post-marketing clinical trials were conducted in the United States and Europe, respectively.
① CARES study
The randomized, double-blind, allopurinol-controlled Cardiovascular Outcomes Study (CARES) was conducted to evaluate the cardiovascular risk of this drug. This study compared the risk of Major Adverse Cardiovascular Events (MACE) between patients treated with this drug (n = 3,098) and patients treated with allopurinol (n = 3,092).
The primary end point was the first occurrence of a Major Adverse Cardiovascular Event (MACE), defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or unstable angina following urgent coronary revascularization. This study was designed to exclude the risk difference by a pre-specified amount of 1,3 for the cumulative risk function ratio of MACE (Major Adverse Cardiovascular Events). An independent committee conducted a blind evaluation of serious adverse cardiovascular events according to predefined criteria to determine Major Adverse Cardiovascular Events (MACE). The study was event-driven and patients were followed until a sufficient number of major outcome events occurred. The median follow-up period during the study was 2.6 years.
The randomly selected group receiving this drug initially received 40 mg once daily, and if serum uric acid was 6 mg/dL or higher for 2 weeks, the dose was increased to 80 mg once daily. Randomly selected groups receiving allopurinol, those with normal renal function or mild renal dysfunction (estimated creatinine clearance greater than 60 ml/minute but less than 90 ml/minute), initially received 300 mg once daily and the dose was increased monthly by 100 mg/day until serum uric acid was less than 6 mg/dL or a dose of 600 mg allopurinol once daily was achieved; Patients with severe renal insufficiency (creatinine clearance greater than 30 ml/minute but less than 60 ml/minute) were initially administered 200 mg once daily, and the dose was increased monthly by 100 mg/day until serum uric acid was less than 6 mg/dL or a dose of 400 mg allopurinol once daily was achieved.
The average age of the population was 65 years (range: 44 to 93 years). Most patients were male (84%) and white (69%). The patients had been diagnosed with gout for approximately 12 years, had a mean serum uric acid of 8.7 mg/dL, and 90% had experienced at least one gout attack in the past year. Cardiovascular history included myocardial infarction (39%), hospitalization for unstable angina (28%), cardiovascular reintervention (37%), and stroke (14%).
The most common comorbidities were hypertension (92%), hyperlipidemia (87%), diabetes (55%), diabetes with microvascular and/or macrovascular disease (39%), and renal impairment (92% had creatinine clearance of 30–89 mL/min). Cardiovascular medication use was balanced across treatment groups and included ACE inhibitors or ARBs (70%), lipid-lowering medicines (74%), aspirin (62%), beta-blockers (59%), calcium channel blockers (26%), and non-aspirin antiplatelet medicines (31%). The study results for the primary major adverse cardiovascular event (MACE) endpoint and its individual components are presented below. For the composite primary endpoint, this medicine was non-inferior to allopurinol.
The incidence of nonfatal myocardial infarction, stroke, and unstable angina following emergency coronary revascularization was similar. Cardiovascular mortality was higher in patients treated with this drug (134 cardiovascular deaths, 1.5 per 100 patients over 1 year) than in patients treated with allopurinol (100 cardiovascular deaths, 1.1 per 100 patients over 1 year). Acute cardiovascular death was the most common cause of adjudicated cardiovascular death in the allopurinol group (83 of 3,098, 2.7%) compared to allopurinol (56 of 3,092, 1.8%). The biological plausibility of cardiovascular deaths associated with this drug is unclear.
All-cause mortality was higher in the allopurinol group (243 deaths, 7.8%, 2.6 per 100 people) than in the allopurinol group (199 deaths, 6.4%, 2.2 per 100 people) due to a higher rate of cardiovascular deaths. It came out high. [Hazard Ratio: 1.22, 95% confidence interval: 1.01, 1.47]

[Table 4] MACE (Major Adverse Cardiovascular Events) incidence rate in the CARES study
※ Refer to the manual

② FAST study
A prospective, randomized, open-label, endpoint-blinded, multicenter, non-inferiority-proof design (FAST) follow-up post-registration study was conducted to evaluate the cardiovascular risk of this drug. Among 6,128 patients with chronic hyperuricemia aged 60 years or older (median: 6 years) who had at least one cardiovascular risk factor and were taking allopurinol, the cardiovascular safety was compared between 3,063 patients treated with this drug and 3,065 patients treated with allopurinol.
The primary endpoint was the time to the first occurrence of the composite endpoint, defined as cardiovascular death, hospitalization for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome, or non-fatal stroke, with a non-inferiority margin of 1.3. An independent committee conducted evaluations according to predefined criteria for determination of clinical events (primary composite endpoint, secondary cardiovascular endpoint, and death). The study followed a sufficient number of patients to collect the primary endpoint, with a median follow-up period of 1,467 days (IQR 1,029-2,052).
Serum uric acid concentration was measured at the screening visit before randomization, and if the existing allopurinol dose was not adjusted below the EULAR target value (0.357 mmol/L (<6 mg/dL)), the dose was increased by 100 mg/day every two weeks until the patient's uric acid concentration reached the target value or the maximum permitted dose (900 mg/day) or the maximum tolerated allopurinol dose. A lead-in phase was conducted.
The randomly selected group received 80 mg per day for the first two weeks, and after two weeks, if serum uric acid did not reach the EULAR target, the dose was increased to 120 mg per day. The randomly selected allopurinol administration group took allopurinol at the optimal dose determined before randomization.
The mean age of the population was 71 years (standard deviation: 6.4), and most patients were male (85.3%) and white (99.1%). The patients took allopurinol to treat gout for about 6 years, and the average serum uric acid was 0.297 mmol/L. Cardiovascular history included coronary revascularization (12%), angina pectoris requiring medical treatment (12%), myocardial infarction (11%), acute coronary syndrome (10%), stroke (5%), transient ischemic attack (5%), or heart failure (5%).
The most common comorbidities were diabetes (23%), kidney disease (16%), asthma (11%), and chronic obstructive pulmonary disease (7%). The use of cardiovascular medications was balanced between treatment groups. Cardiovascular disease medications included: ACE inhibitors (40%), statins (59%), antiplatelet agents including aspirin (35%), and aspirin (30%).
The research results on the items and individual components of the composite evaluation variable, which is the primary evaluation variable, are as follows. For the primary endpoint, the group using this drug (172 composite endpoints, 1.723 per 100 patients over 1 year) was not inferior to the allopurinol group (241 composite endpoints, 2.054 per 100 patients over 1 year) [risk ratio: 0.85, 95% confidence interval: 0.70-1.03]. Among the secondary endpoints, the cardiovascular mortality rate was lower in the drug-treated group (62 cardiovascular deaths, 0.610 per 100 patients over 1 year) than in the allopurinol group (82 cardiovascular deaths, 0.677 per 100 patients over 1 year) [hazard ratio: 0.91, 95% confidence interval: 0.66, 1.27].
For the individual components of the primary endpoint: the incidence of cardiovascular death, hospitalization for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome, and non-fatal stroke, the drug use group was not inferior to the allopurinol group.
In addition, a subgroup analysis was conducted on patients with a history of myocardial infarction, stroke, or acute coronary syndrome for the primary endpoint, and results were similar between the two groups (65 patients (9.5%) in the drug-treated group and 83 patients (11.8%) in the allopurinol group [hazard ratio: 1.02, 95% confidence interval: 0.74-1.42].
In contrast to the previous CARES study, this study found no signs of increased all-cause mortality or cardiovascular mortality with this drug compared to allopurinol. Overall, there were fewer deaths in the allopurinol group (82 cardiovascular deaths and 174 all-cause deaths) in the drug-treated group (62 cardiovascular deaths and 108 all-cause deaths).

[Table 5] Primary endpoint (composite endpoint) and cardiovascular mortality of the FAST study
※ Refer to the manual

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Fexot tab.40mgPrecautions for use2023.01.02PDFPrecautions for use of Febuxostat single agent (content 40, 80 mg, film-coated tablet).pdf